Modern Setup Host Windows 10
Kroger Feedback

Blog

Live Blog | SDPA Summer Conference 2016

LIVE BLOG | Acne Vulgaris: A Time to Challenge the Current View

In this live blog from the SDPA Annual Summer Dermatology Conference in Austin, TX, Kristine Kucera, PA-C, MPAS, DHS presented a product theater for Valeant Pharmaceuticals called “Acne Vulgaris: A Time to Challenge the Current View.

Highlights:

  • Onexton (clindamycin phosphate and benzoyl peroxide gel 1.2%/3.75%) is approved for the treatment of acne vulgaris in people 12 years old and older.
  • Onexton was shown to be effective in patients with moderate to severe comedonal and inflammatory acne.
  • Onexton is well tolerated and no patients withdrew from a key clinical trial due to adverse effects or inefficacy.
  • Onexton addresses three of the four causes of acne: inflammation, bacterial colonization with p. acnes, and cell turnover.
  • Onexton is micronized and microdisbursed – this means its small molecule size allows for even dosing and distribution across the skin.

More:

Ms. Kucera described Valeant Pharmaceuticals Onexton (clindamycin phosphate and benzoyl peroxide gel 1.2%/3.75%) gel for the treatment of acne vulgaris in people age 12 years or older.

Ms. Kucera said that Onexton addresses three of the four main causes of acne: inflammation, colonization with p. acnes, and cell turnover, noting the drug’s anti-inflammatory and anti-bacterial properties.

She noted that patients need to apply one, pea-sized amount to the face per day. She said that Onexton is micronized and microdisbursed, which ensures even dosing and even distribution across the skin when applied. Onexton contains a humectant that hydrates the skin and does not contain alcohol.

Ms. Kucera highlighted the results of a clinical trial involving patients with moderate to severe comedonal and inflammatory acne. After 12 weeks of treatment, comedonal acne decreased approximately 60% and inflammatory acne decreased approximately 70% in adult women compared to 34% and 40%, respectively using vehicle only. Similar results were found in adolescent girls treated with Onexton.

Ms. Kucera noted that Onexton is well-tolerated with less than 0.5% of patients reporting burning, contact dermatitis, pruritis, and rash. No patients withdrew from the study, either from adverse effects or inefficacy.




Our Sponsors